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Abstract: Diabetic foot infections (DFIs) represent one of the most frequent and disabling morbidities
of longstanding diabetes; therefore, early diagnosis is mandatory. The aim of this multicenter
retrospective study was to compare the diagnostic accuracy of white blood cell scintigraphy (WBC),
18F-fluorodeoxyglucose positron emission tomography/computed tomography ((18F) FDG PET/CT),
and Magnetic Resonance Imaging (MRI) in patients with suspected DFI. Images and clinical data
from 251 patients enrolled by five centers were collected in order to calculate the sensitivity, specificity,
and accuracy of WBC, FDG, and MRI in diagnosing osteomyelitis (OM), soft-tissue infection (STI),
and Charcot osteoarthropathy. In OM, WBC acquired following the European Society of Nuclear
Medicine (EANM) guidelines was more specific and accurate than MRI (91.9% vs. 70.7%, p < 0.0001
and 86.2% vs. 67.1%, p = 0.003, respectively). In STI, both FDG and WBC achieved a significantly
higher specificity than MRI (97.9% and 95.7% vs. 83.6%, p = 0.04 and p = 0.018, respectively).
In Charcot, both MRI and WBC demonstrated a significantly higher specificity and accuracy than
FDG (88.2% and 89.3% vs. 62.5%, p = 0.0009; 80.3% and 87.9% vs. 62.1%, p < 0.02, respectively).
Moreover, in Charcot, WBC was more specific than MRI (89.3% vs. 88.2% p < 0.0001). Given the
limitations of a retrospective study, WBC using EANM guidelines was shown to be the most reliable
imaging modality to differentiate between OM, STI, and Charcot in patients with suspected DFI.
Keywords: diabetic foot; infection; diagnosis; WBC scintigraphy; FDG PET/CT; MRI
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1. Introduction
Diabetes-related foot complications represent some of the most frequent and disabling morbidities
of longstanding diabetes and are associated with prolonged hospitalization and high social costs [1–5].
Patients with peripheral neuropathy and microvascular impairment have an increased risk of
developing an ulcer that could represent a breach for the entry of bacteria, thus potentially causing an
infection. The process initially involves the soft tissues (STs) of the foot, and later it could spread in depth
for contiguity and reach the bone, leading to diabetic foot osteomyelitis (DFO). Osteomyelitis (OM) is a
severe complication for the diabetic patient, with a high risk of amputation and mortality rates [6–8].
Considering that more than 50% of wounds are infected at their presentation [2], the prevention of
foot ulcers, early diagnosis, and appropriate and prompt treatment are mandatory in order to avoid
such a complication and amputation [9,10]. Moreover, about 2.5% of diabetic patients have a Charcot
foot, a progressive degenerative disease of the musculoskeletal system characterized by destruction of
the bony architecture, which usually involves tarsal and metatarsal joints [11]. The presence of this
neuro-ostearthropathy further complicates the diagnostic approach to diabetic foot infection (DFI)
since this condition may coexist with the presence of ulcers, thus making the correct diagnosis difficult
to achieve. Nevertheless, a differential diagnosis between Charcot, OM, and soft tissue infection (STI)
is crucial for the correct management in patients suspected of DFI.
The gold standard examination for the diagnosis of OM is represented by the isolation of the
pathogen using microbiological assays. Bone biopsy, however, is an invasive procedure and its reliability
strongly depends on the quality of the specimen obtained in the aseptic procedure. Moreover, clinical
examination and biochemical inflammatory markers are often non-specific and do not allow a
differentiation between infection and inflammation [12,13]. Several diagnostic imaging tests are
currently available, including both radiological and nuclear medicine (NM) non-invasive imaging
modalities. Despite a consensus document for the diagnosis of peripheral bone infections being
recently published, it does not specifically address DFI [14]. Therefore, at present, no clear consensus
on the most appropriate imaging technique in suspected DFI exists [7,15,16]. Magnetic resonance
imaging (MRI) is the best radiological modality for the assessment of soft tissue abnormalities and may
be able to differentiate between STI and OM. However, its specificity can be reduced in the presence
of bone marrow edema, synovial effusion, dislocation, bony destruction, and loss of discernible
bone and joint margins since they may characterize neuropathic joint disease as well as OM [17].
The NM gold standard in this field is represented by white blood cell scintigraphy (WBC), which
provides an in vivo demonstration of the presence of the infective focus. The European Society of
Nuclear Medicine (EANM) has previously published guidelines [14,18–22], aiming to define the
correct labelling procedure, acquisition, and interpretation criteria for WBC. However, currently,
not all institutes follow these recommended standards. The use of 18F-fluorodeoxyglucose ((18F)
FDG) positron emission tomography combined with computed tomography (PET/CT) has gained a
role in several indications in the field of infection and inflammation [21]. This technique is widely
available and has the advantages of a short acquisition time, high image resolution, and no need
of blood handling and manipulation. FDG, however, accumulates in both infection and sterile
inflammation since all the involved cells use glucose as a source of energy [21]. Therefore, it is not
clear if FDG PET/CT is adequate enough to discriminate among the different foot complications in
diabetic patients [15]. In a recently published systematic review and meta-analysis comparing WBC,
FDG PET/CT, and MRI in DFO, it emerged that the sensitivity is approximately 90% for all imaging
modalities, with 99mTechnetium-hexamethylpropyleneamine oxime (99mTc-HMPAO)-labelled WBC
scintigraphy demonstrating the highest specificity, followed by FDG PET/CT, MRI, and 111Indium
(111In) oxine-labelled WBC [23].
To the best of our knowledge, no multicenter studies are available in the literature comparing these
imaging modalities. Therefore, the aim of this retrospective study was to compare the accuracy of WBC
scintigraphy, FDG PET/CT, and MRI in differentiating OM, STI, and Charcot in patients with suspected
DFI. In particular, our primary end point was to evaluate the diagnostic approaches adopted among
J. Clin. Med. 2020, 9, 1645 3 of 16
different centers in daily practice, aiming to provide a panoramic view on the diagnostic management
in different countries. Moreover, since it is well known that the accuracy of WBC scintigraphy relies
on the application of the correct acquisitions protocols, image display, and interpretation criteria,
the secondary end point of this study was to evaluate, on a multicenter scale, the impact of recently
published EANM guidelines [20] on the diagnosis of DFI.
2. Experimental Section
2.1. Materials and Methods
This retrospective multicenter study included five centers from The Netherlands, Italy, Israel,
Greece, and Spain. Data from consecutive patients affected by diabetic foot complications between
June 2008 and June 2014 were locally collected by each center, then merged in a single central database,
and processed using SPSS statistic software. This study was approved by each local ethical committee
and of the coordinating center (Groningen, the Netherlands).
2.1.1. Patients
Patients were retrospectively recruited by radiology and NM departments of each center where
they were sent by the respective local diabetic foot units (DFUs), between 2008 and 2014, for the study
of suspected DFI. The following inclusion and exclusion criteria were adopted in this study:
Inclusion criteria (the first four items were mandatory):
• Type 1 or type 2 diabetes treated with oral medications or insulin;
• Suspected DFI based on clinical presentation of foot wounds according to Perfusion, Extent, Depth,
Infection, Sensation of Infectious Diseases Society of America (PEDIS/IDSA) classification [1];
• At least one out of the three imaging modalities performed for suspected DFI;
• Final diagnosis provided by gold standard;
• Bony abnormalities detected by plain radiographs;
• Palpable bone at “probe-to-bone test” (in presence of open wounds); and
• Raised inflammatory markers.
Exclusion criteria:
• Lack of information on final diagnosis; and
• Patients lost at clinical follow-up.
Demographic and laboratory data, including gender, age, type of diabetes, medical history,
biochemistry, microbiology, histopathology, treatments, and final diagnosis, were collected by each
center. In patients in whom more than one infection was investigated, each episode was considered as
an individual event with corresponding imaging.
Patients were clinically or surgically managed by the DFUs of each center following their
own protocols.
2.1.2. Imaging Modalities and Analysis
Information regarding the camera type, manufacturer, year of manufactory, the use of markers
or contrast, details of the compounds, and sequences for MRI were recorded. For NM examinations,
information on radiopharmaceutical, administered activity, type of gamma-camera, equipped or not
with single-photon emission tomography/computed tomography (SPECT/CT), PET/CT camera systems,
and exact protocols of acquisition were also specified by each center. All acquisition details and DICOM
files had to be available in order to include the patients in the study. NM images were examined by
two experienced NM physicians. Discordant cases were resolved by consensus. All MRI scans were
evaluated by an experienced radiologist. All readers were blinded for clinical details. The following
scoring method was used for each diagnostic tool in order to classify the outcome: 0 = negative/sterile
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inflammation; 1 = OM; 2 = STI; 3 = Charcot. If two or more conditions were concomitant in the same
patient, the most clinically relevant was considered (e.g., OM + Charcot = OM; OM + STI = OM; STI +
Charcot = STI).
For each scan, the location of disease (in forefoot or mid/hindfoot) was recorded.
2.1.3. Interpretation Criteria for WBC Scintigraphy
• Acquired according to EANM recommendations: Interpretation criteria were used as recommended
by the guidelines [20] and obtained by both visual and, in equivocal cases, semi-quantitative analysis
by drawing region of interests (ROIs) on target (T) and contralateral side as background (B) in order
to calculate the T/B ratio. OM was defined when WBC focal accumulation at 20–24 h was higher
in intensity than at 3–4 h. STI was defined when WBC focal or diffuse accumulation at 20–24 h
was lower than at 3–4 h. Charcot was defined when diffuse WBC accumulation at 20–24 h was
similar or decreased compared to the uptake at 3–4 h.
• Acquired not according to EANM recommendation: In the case scans were performed with only
one time point acquisition, they were classified as follows: OM was defined when the WBC focal
accumulation was higher than surrounding tissues. STI was defined when WBC accumulation
(both focal or diffuse) was observed in the superficial regions of the foot. Charcot was defined
when diffuse WBC accumulation at the mid/hindfoot was observed.
2.1.4. Interpretation Criteria for FDG PET/CT
FDG PET/CT assessment was performed using a visual analysis describing the target areas in
terms of intensity (grade 0: no uptake; grade 1: uptake at foot location = contralateral side; grade 2:
uptake at foot location > contralateral side), pattern of uptake (focal vs. diffuse), number of foci, and the
exact localization of the increased uptake as provided by the CT. We also performed a semi-quantitative
analysis using the maximum and mean standardized uptake values (SUVmax, SUVmean) of each
area with increased uptake. The SUVmax ratio (SUVmax of target/SUVmax contralateral background)
was also calculated. OM was defined when focal or diffuse FDG uptake higher than the contralateral
side was visible on the bone structure with or without soft tissue involvement. STI was defined
when focal or diffuse FDG uptake (grade 1 or 2) was visible only in the soft tissues without bony
involvement. Charcot was defined when diffuse FDG uptake (grade 1 or 2) was visible involving tarsal
and metatarsal joints and associated with bone destruction on CT.
2.1.5. Interpretation Criteria for MRI
MRI was evaluated for primary and secondary signs of OM, according to the literature [24–26].
Briefly, OM was defined in the presence of low medullary bone marrow signal in a geographic confluent
pattern on T1-weighted imaging (T1w), concordant with abnormal (high) signal at fat-suppressed
T2-weighted (T2w) and post-gadolinium (Gd) T1w imaging.
Secondary signs of OM were also evaluated [24]:
(a) Ulcer (skin interruption with raised margins and associated soft tissue defect);
(b) Sinus tract (“tram track” pattern post-Gd enhancement);
(c) Cellulitis (skin thickening and soft tissue edema with low T1 and T2 signal and post-Gd enhancement);
(d) Abscesses (signal intensity of fluid with post-Gd peripheral rim-like enhancement);
(e) Gangrene (post-Gd non-enhancing area of devitalized tissue that is sharply demarcated from
surrounding viable tissue, without (dry gangrene) or with air bubbles in the soft tissue
(wet gangrene)); and
(f) Tenosynovitis (area of post-Gd peri-tendinous enhancement coursing through an area of cellulitis
and adjacent to an infected ulcer).
STI was considered present if at least one of the previously described findings was observed
without any radiological signs of bone involvement. Charcot was defined as the presence of soft tissue
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edema, fluid collections, effusions, bone marrow abnormalities, post-Gd peri-articular soft-tissue,
and bone marrow enhancement (typically in the tarsal-metatarsal and metatarsal-phalangeal joints),
associated with deformities and osseous fragmentation.
2.1.6. Therapeutic Management
The different therapeutic strategies adopted by the DFUs of each local center were recorded when
available, and were classified as follows:
• No treatment (including offloading);
• Conventional wound care and topic antibiotic treatment;
• Systemic antibiotic treatment; and
• Surgery (debridement or amputation).
When possible, the results of the three imaging modalities were correlated with the treatment
received by the patient.
2.1.7. Gold Standard
Bone biopsies were used as gold standard for the final diagnosis of OM and Charcot, independently
by the availability of the isolated pathogen. Skin cultures were used for the diagnosis of STI. When bone
biopsies or skin cultures were not available, a clinical follow-up of at least 12 months was used in order
to confirm or rule out the diagnosis achieved with imaging modalities.
2.1.8. Statistical Analysis
All statistical analyses were performed using SAS version 9.4 and JMP version 14 (SAS Institute,
Cary, NC, USA). Categorical variables are expressed as absolute frequencies and percentages.
Continuous variables (SUVmax and SUVmax ratio) are presented in mean ± standard deviation
(SD) mean differences across groups (OM, STI, and Charcot) and were compared by generalized linear
models. The normality of the residuals was verified by Shapiro–Wilk test and homoscedasticity by
the Levene and Brown–Forsythe test. Differences between the final diagnosis (no pathology, OM,
and STI) vs. C-reactive protein (CRP) and erythrocytes sedimentation rate (ESR) were evaluated
by the Kruskal–Wallis test and Steel–Dwass test using post hoc analysis. The sensitivity, specificity,
and diagnostic accuracy of all the three imaging modalities in diagnosing OM, STI, and Charcot foot
against the reference standard histology and/or clinical follow-up were performed by routine use of
SAS. Comparisons of the sensitivity, specificity, and diagnostic accuracy between the three imaging
modalities were performed using the Z test for the equality of two proportions. The Benjamini–Hochberg
procedure was applied to check multiple comparisons. The results are reported in a percentage with
95% confidence intervals (CIs). A p-value <0.05 was considered statistically significant.
3. Results
A total of 251 patients were enrolled in the contributing five centers (Scheme 1). A descriptive
analysis of our population is summarized in Table 1.
Post hoc analysis on median values of CRP and ESR showed that they were both significantly
higher in patients with OM compared with patients without any infection (p = 0.017 and p = 0.027
respectively) as illustrated in Figure 1. No similar significant difference was observed between patients
with STI and normal subjects and between patients with OM and STI.
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Causative pathogens were recorded in 67 patients that underwent skin cultures, and in 14 out
of 50 patients who performed (pre- or intra-operative) biopsy; however, biopsy was used as a gold
standard for final diagnosis in the other 36 patients in which we could not obtain information on
the pathogen causing the infection. In the remaining 121 patients, final diagnosis was assessed with
clinical follow-up (see Table 2). OM was found in 93 patients, STI in 76, and Charcot in 10 patients.
The remaining 72 subjects had no pathology according the reference standard. Regarding the imaging
modalities, 119 patients underwent a WBC scintigraphy, 46 FDG PET/CT, and 59 patients underwent
MRI. In 10 patients, both WBC and FDG PET/CT were performed; in 15 patients, both WBC scintigraphy
and MRI; and in 2 patients, all three imaging techniques were performed. The diagnostic performances
of the three imaging modalities are summarized in Table 3.
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OM (WBC *) 59.1 (38.5–79.6) 77.3 (67.2–87.4) 72.7 (63.4–82.0)
STI (WBC *) 29.7 (15.0–44.5) 86.3 (76.8–95.7) 62.5 (52.4–72.6)
Charcot (WBC *) n.c. 92.0 (86.4–97.7) n.c.
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OM (FDG PET/CT) 69.0 (52.1–85.8) 72.4 (56.1–88.7) 70.7 (59.0–82.4)
STI (FDG PET/CT) 27.3 (1.0–54.0) 97.9 (93.7–100) 84.5 (75.2–93.8)
Charcot (FDG PET/CT) n.c. 62.5 (49.8–75.2) 62.1 (49.6–74.6)
OM (MRI) 62.9 (46.8–78.9) 70.7 (56.8–84.7) 67.1 (56.5–77.7)
STI (MRI) 42.9 (21.7–64.0) 83.6 (73.9–93.4) 72.4(62.3–82.4)
Charcot (MRI) n.c. 88.2 (80.6–95.9) 80.3 (71.3–89.2)
* WBC scans acquired without following EANM guidelines; ** WBC scans acquired following EANM guidelines;
n.c. = not calculated because of the low number of patients. FDG PET/CT, fluorodeoxyglucose positron emission
tomography/computed tomography.
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3.1. WBC Scintigraphy
The mean administered activity of 99mTc-radiolabelled leukocytes was 569.8 ± 116.5 MBq
(15.4 ± 3.15 mCi).
Since a significant discrepancy was observed among the different centers regarding the acquisition
procedure, we compared the results obtained by centers that applied EANM guidelines with those
who did not follow these recommendations. Fifty-eight scans were acquired according to the EANM
guidelines for WBC scintigraphy with acquisition times corrected for Tc-99m decay at two (4 and
24 h) or three times points (30’, 3 h, and 20 h) [20] (Figure 2). Eighty-eight scans did not follow these
recommendations; in particular, 73 scans (83.0%) were acquired only 4 h post injection (p.i.) and 15
(17.0%) were acquired at 2 time points, 1 and 4 h p.i. Furthermore, given the low number of patients
who performed combined SPECT/CT in these two groups that did not allow us to make a comparative
analysis, we considered only planar images for the diagnosis, thus exploring the importance of multiple
time-point acquisitions.
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diagnosis of STI; (b) Multi Intensity Projection (MIP) and transaxial views of FDG PET/CT, of the 
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Figure 2. (a) Planar images of the WBC scan acquired with correction for 99mTechnetium (99mTc) decay
at 3 h (on the left) and 20 h (on the right). The focal uptake of labelled leukocytes detectable on the
plantar surface of the left foot decreases between the 3 and 20 h images, being consistent with the
diagnosis of STI; (b) Multi Intensity Projection (MIP) and transaxial views of FDG PET/CT, of the
same patient, show the focal uptake in the plantar surface of the left foot in correspondence with a
cutaneous/subcutaneous ulcer of the soft tissues. Bone and soft tissue biopsies confirmed the diagnosis
of STI and the patient was treated with topic antibiotic therapy. WBC: white blood cells scintigraphy;
FDG PET/CT, fluorodeoxyglucose positron emission tomography/computed tomography.
The sensitivity, specificity, and accuracy of the labelled WBC planar images of the two groups are
reported in Table 3.
3.2. FDG PET/CT.
FDG PET/CT scans were generally acquired 60 min after the injection of approximately 3 MBq
(0.08 mCi)/kg of FDG according to EANM guidelines [21]. Both qualitative assessment (intensity and
pattern of uptake) and semiquantitative analysis of FDG uptake were performed (Table 4).
Table 4. Pattern of FDG PET/CT in the study population.
Final Diagnosis
Intensity SUVmax
(Mean ± SD 1)
SUVmax Ratio
(Mean ± SD 1)Focal Uptake (%) Diffuse Uptake (%)
OM 62.1 37.9 5.3 ± 2.1 3.9 ± 2.4
STI 54.5 45.5 5.4 ± 1.8 4.2 ± 2.1
Charcot 0 100 4.9 ± 1.9 4.9 ± 1.6
1 SD: Standard deviation.
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In total, 96.5% of patients with a final diagnosis of OM (29 patients) showed “grade 2 uptake” that
was focal in 62.1% (18 patients) of cases and diffuse in the remaining 37.9% (11 patients). The mean
values of the SUVmax and SUVmax ratio were 5.3 ± 2.1 and 3.9 ± 2.4, respectively. All patients with
STI (11) showed “grade 2 uptake” and it was focal in 54.5% of cases (6 patients) and diffuse in
the remaining 45.5% of cases (5 patients). The mean values of the SUVmax and SUVmax ratio were
respectively 5.4 ± 1.8 and 4.2 ± 2.1. Only two patients with Charcot were studied with FDG PET/CT
and they all patients showed “grade 2” and diffuse uptake. The mean values of the SUVmax and
SUVmax ratio were respectively 4.9 ± 1.9 and 4.9 ± 1.6. The semiquantitative analysis did not provide
a significant difference in terms of both the SUVmax and SUVmax ratio between the three groups of
patients (p = 0.48 and p = 0.83, respectively). The sensitivity, specificity, and accuracy for FDG PET/CT
are reported in Table 3.
3.3. MRI
All centers used similar protocols of acquisitions that included at least T1w, fat-suppressed
T2w, and post-Gd T1w sequences, with fat suppression or with subtraction of pre- and post-Gd T1w.
Sequences were acquired in at least two perpendicular planes.
The sensitivity, specificity, and accuracy for MRI are reported in Table 3.
3.4. Comparison between WBC Scintigraphy, FDG PET/CT, and MRI in Suspected DFI
WBC scintigraphy, in particular if acquired according to EANM guidelines, showed significantly
higher specificity and accuracy than MRI (p < 0.0001 and p = 0.003, respectively) in detecting OM.
Moreover, the sensitivity, specificity, and accuracy of WBC scintigraphy were higher than FDG PET/CT,
although not statistically significant. In STI, both FDG PET/CT and WBC scintigraphy achieved a
significantly higher specificity than MRI (p = 0.04 and p = 0.018, respectively). The sensitivity of the
three imaging modalities in detecting Charcot could not be calculated because of the low number of
patients, but both MRI and WBC scintigraphy showed significantly higher specificity and accuracy than
FDG PET/CT (p = 0.0009 and p = 0.029, respectively, for MRI and p = 0.0009 and p = 0.003, respectively,
for the radiolabeled WBC scan). Moreover, WBC scintigraphy provided significantly higher specificity
than MRI (p < 0.0001) in this condition. However, these results were based on only a small sample size.
3.5. Comparison between WBC Scintigraphy Performed according and not according to EANM Guidelines
In both OM and STI, using standardized protocols resulted in an overall increase of the sensitivity
(from 59.1 to 76.2% and from 29.7% to 75%, respectively), specificity (from 77.3% to 91.9% and from
86.3% to 95.7%, respectively), and diagnostic accuracy (from 72.7% to 86.2% and from 62.5% to
91.4%, respectively) in comparison to those who did not use these protocols. Statistical significance
was reached when comparing the sensitivity (p = 0.006) and diagnostic accuracy (p < 0.0001) in
the evaluation of STI. In Charcot, due to the low number of the subjects (only two patients in the
“EANM-approved protocols” group and none in the other), this comparison could not be done.
3.6. Comparison between WBC Scintigraphy, FDG PET/CT, and MRI according to the Location of Disease
We compared the performance of the three imaging modalities in the forefoot and mid/hindfoot
disorders (Table 5).
Patients without any histopathology results (28.6%) according to the reference and patients with
Charcot (only 3.9% of whole population) were excluded. FDG PET/CT was more specific than MRI
in detecting STI in mid/hindfoot (p = 0.03). For the detection of OM, WBC scintigraphy showed
significantly higher sensitivity in the forefoot rather than the mid/hindfoot (p = 0.013). Similarly, FDG
showed significantly higher sensitivity and accuracy in detecting OM of the forefoot compared to the
mid/hindfoot (p = 0.026 and p = 0.015, respectively).
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Table 5. Comparison between the performance of WBC scintigraphy, FDG PET/CT, and MRI in
detecting OM and STI according to the location.
Sensitivity (%) (95% CI) Specificity (%) (95% CI) Accuracy (%) (95% CI)
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3.7. Correlation between the Findings of Diagnostic Tests and Therapeutic Management
A descriptive analysis of the different therapeutic options conducted in the studied population,
according to the final diagnosis, is summarized in Tables 6 and 7. Most patients with final diagnosis of
OM (64.4%) underwent surgery and 32.8% were treated with antibiotics. WBC scintigraphy correctly
identified 77% and 83% of these patients, FDG identified 83% and 50% of them, and MRI identified
65% and 73% of them.
Table 6. Different therapeutic strategies in patients with final imaging diagnosis of OM.
Therapeutic Strategy in OM Diagnosis according to Imaging Modalities (%)
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Table 7. Different therapeutic strategies in patients with final imaging diagnosis of STI.







































































By contrast, most patients with a final diagnosis of STI (68.3%) were treated with antibiotics and
only 15% underwent surgery. WBC scintigraphy correctly identified 39% and 72% of these patients
while MRI identified 47% and 66% of them.
Since we did not observe any statistically significant difference between the three imaging
modalities in therapy decision-making, we can conclude that they have similar accuracy in guiding
clinicians for the correct management of patients affected by OM or STI.
4. Discussion
This retrospective multicenter study is, to the best of our knowledge, the first to compare the
diagnostic value of WBC scintigraphy, FDG PET/CT, and MRI in a large population of patients with
suspected DFI, with a particular emphasis on the ability of these imaging modalities to differentiate
between OM, STI, and Charcot. At present, no similar studies are available in the literature, probably
reflecting the heterogeneity in the diagnostic approaches used in patients from different countries.
We believe that a consensus on the most appropriate imaging tool for the assessment of OM, STI,
and Charcot is necessary in order to standardize the management of these patients in all centers.
Our analysis shows that the radiolabeled WBC scintigraphy, especially if acquired according to
EANM guidelines, has an overall high diagnostic performance in OM, STI, and Charcot, in particular,
in terms of the specificity and diagnostic accuracy.
It is well known that when adhering to standardized protocols for labelling, acquisition, image
display, and interpretation, the accuracy of WBC scintigraphy in detecting different kinds of infection
can be increased [20,27,28]. In our population, 58 patients were studied according to the EANM
guidelines for WBC image acquisition and display, while 88 scans did not follow these recommendations.
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In these 88 patients, clear superiority of the WBC scan over FDG PET/CT and MRI did not emerge
neither in OM nor STI and Charcot. On the other hand, comparing the results of WBC scintigraphy
acquired according to EANM guidelines with FDG PET/CT and MRI, we found that the WBC scan was
more accurate and specific than MRI in OM, more specific than MRI in STI, and more specific and
accurate than FDG in Charcot. These results emphasize the importance of using a standardized image
acquisition protocol as suggested by EANM guidelines [20].
Furthermore, comparing the results of WBC scintigraphies acquired according to the EANM
guidelines versus WBC acquired without following these recommendations, we found a statistically
significant difference in the sensitivity (p = 0.006) and diagnostic accuracy (p < 0.0001) in the evaluation
of STI. This is extremely important considering that STI in diabetics is a particular type of infection
that cannot be managed as a common STI in other areas or in non-diabetic patients [29]. The presence
of microangiopathy and neuropathy can impair tissue healing and treatment efficacy, with possible
progression in OM. Therefore, the diagnosis of STI must be prompt and accurate. In OM, we also found
a better specificity (p = 0.06) and accuracy (p = 0.05) in patients acquired with the EANM protocol
than in patients acquired with non-EANM protocols, despite the statistical significance being low.
111In-oxine could also be used as an alternative to 99mTc-HMPAO for the labelling of WBC and it is
also able to provide a high accuracy in detecting an infection [19,20]; however, due to its physical
characteristics and radiation burden, 99mTc remains the preferred agent.
FDG PET/CT has gained an important role in the diagnosis and follow-up of several infective
and inflammatory diseases, but it is still unclear whether it could represent a valid alternative to WBC
scintigraphy in DFI [15,21]. Moreover, the diagnostic performance of this modality mostly relies on the
CT scan, which allows correct anatomical localization and evaluation of the extent of FDG uptake [30].
In our population, FDG PET/CT showed a higher specificity compared with MRI (respectively 95.7% vs.
83.6%) in detecting STI, especially in the mid/hindfoot. This may be explained by the use of CT, which
improves the localization of the uptake to soft tissues, thus facilitating the achievement of a correct
diagnosis and justifying the low number of false positive results with FDG PET/CT. Nevertheless,
as explained above, in STI, the sensitivity is more important than the specificity and, to this regard, WBC
showed better sensitivity than FDG. Moreover, we found a good sensitivity, specificity, and accuracy of
FDG PET/CT in detecting pedal OM, especially in the forefoot. Although precise interpretative criteria
exist for WBC scintigraphy, they are not applicable for FDG PET/CT. Several authors investigated
the possible role of SUV measurements in the diagnosis of infectious processes, but the results are
discordant among different studies [31–33]. For example, Basu et al. [31] found higher SUVmax values
in patients with OM compared with patients with Charcot and uncomplicated DF (2.9–6.2 vs. 0.7–2.4
vs. 0.2–0.7), concluding that SUV could be a useful parameter for differentiating these conditions.
Conversely, other authors did not find any significant correlation between SUVmax values and STI,
OM, or Charcot, concluding that SUV alone is not sufficient for diagnosis [15,32,34]. In agreement with
this view, in our population, SUVmax and SUVmax ratios did not significantly differ among patients
with OM, STI, and Charcot. Qualitatively, we found a diffuse tracer uptake in all patients with Charcot
and a focal uptake in the majority of patients affected by OM. In STI, we found more or less the same
proportion of patients with focal and diffuse uptake, thus a precise pattern cannot be determined
in this specific condition. Additionally, the evaluation of intensity was found to not be useful in
discriminating between these three conditions since “grade 2 uptake” was present in almost all patients
studied regardless of the final diagnosis.
In accordance with published meta-analysis and systematic reviews [23,34,35], we found that MRI
was not superior to NM imaging modalities, showing high false positive and false negative rates. In the
literature, the reported sensitivity of MRI in defining OM ranges between 77.0% and 100.0% [36–38],
and, despite its the excellent spatial resolution and natural contrast between different structures, there
are several conditions in which MRI is not accurate (e.g., in post-traumatic or post-operative phases or
in the presence of lower limb ischemia). In this study, we did not exclude patients with peripheral
ischemia, although this condition might have influenced the outcome of MRI [39] and, therefore,
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this aspect should be considered when comparing the diagnostic performance of the three different
modalities. However, lower limb ischemia is a common diagnostic problem that also affects the correct
interpretation of WBC scintigraphy, especially for the detection of STI, since a reduced vascular supply
could impair leukocytes’ recruitment into infected sites [29]. Moreover, in the diabetic foot, the possible
presence of Charcot and mechanical stress can be responsible for changes in the bone marrow or
soft tissue intensity that could be erroneously interpreted as an OM, thus impairing the specificity of
MRI [40–42].
Although it was not a specific aim of our study, we also analyzed the relationship between
inflammatory markers and the final diagnosis of infection and found significantly higher values of CRP
and ESR in patients with OM compared to patients without any infection. However, we did not find
a similar significant difference between patients with STI and normal subjects and between patients
with OM and STI. Moreover, aiming to assess whether these values could be predictive of imaging
outcomes, the analysis revealed that they are not reliable tools to predict a positive result of MRI, WBC
scintigraphy, and FDG PET/CT (data not shown). Indeed, the role of inflammatory markers is much
debated and, although they are usually elevated in infections, they are not able to discriminate the
kind of infection and to evaluate its severity, which could be accurately and non-invasively assessed
only by advanced imaging.
Despite the large number of patients recruited, this study has several limitations. First, the
retrospective nature resulted in a wide heterogeneity of patient selection and diagnostic and therapeutic
approaches adopted among the different centers. Often, the choice of one imaging modality rather
than another was based on local center availability or waiting lists for the scan, and this bias could of
course reflect the comparability of different imaging modalities. Moreover, the different acquisition
protocols adopted of both NM and radiological images could negatively affect the results, as shown in
the group of patients who performed the WBC scan without following the EANM guideline. Another
important limitation is the lack of completeness of the data. In several patients, we missed clinical or
histopathological data. In addition, the lack of SPECT/CT in the majority of cases did not allow us
to consider this imaging modality in the analysis, but only planar images. Finally, the low number
of patients with Charcot does not allow final conclusions to be drawn regarding the best diagnostic
approach in this condition. Moreover, it is well known that bone marrow scintigraphy has a central role
in handling doubtful WBC scintigraphy, and this modality is particularly important in the evaluation
of mid-hindfoot disorders in order to differentiate between an infection from a bone marrow expansion,
which is typical of Charcot foot. Unfortunately, given the retrospective nature of this study, only a few
patients performed bone marrow scintigraphy in addition to WBC scintigraphy, thus not allowing an
evaluation of the added value of this combined approach on the diagnosis.
Nevertheless, retrospective multicenter studies are of clinical value because they consist of data
from centers with different experiences, protocols, and equipment, thus representing the actual real
situation in daily clinical practice for the diagnosis of DFI. In this context, our study underlines the
need for the standardization of acquisition protocols and of interpretation criteria, aiming to correctly
manage patients with suspected DFI. Professionals requesting these imaging tests should be specialists
in the management of DF to reduce the diagnostic and therapeutic variability of IDFs.
The recent availability of PET/MRI may gain an important role in defining the different
complications of the diabetic foot in the near future and it will hopefully solve these challenging clinical
scenarios [43–45].
5. Conclusions
This retrospective study confirms the superiority of WBC scintigraphy over other imaging
modalities in discriminating pedal OM, STI, and Charcot. In particular, when EANM guidelines are
applied, this examination results in high sensitivity, specificity, and accuracy. Additional randomized
powered prospective studies comparing these three imaging modalities, and possibly SPECT/CT and
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PET/MRI in the same patient, are needed to provide a basis for a proper evidence-based multi-modality
diagnostic algorithm.
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